NCT01596621 - A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

August 6, 2012

Primary Completion Date

June 18, 2015

Study Completion Date

April 24, 2017

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

Bendamustine hydrochloride

Bendamustine will be be administered per dose and schedule specified in the arm description.

Trial Locations (27)

100021

Teva Investigational Site 001, Beijing

100029

Teva Investigational Site 026, Beijing

100044

Teva Investigational Site 022, Beijing

100071

Teva Investigational Site 004, Beijing

100142

Teva Investigational Site 003, Beijing

100191

Teva Investigational Site 002, Beijing

100600

Teva Investigational Site 023, Beijing

100730

Teva Investigational Site 016, Beijing

110001

Teva Investigational Site 009, Shenyang

110042

Teva Investigational Site 027, Shenyang

110108

Teva Investigational Site 021, Beijing

130000

Teva Investigational Site 015, Changchun

150081

Teva Investigational Site 019, Harbin

200032

Teva Investigational Site 006, Shanghai

200035

Teva Investigational Site 005, Shanghai

210000

Teva Investigational Site 012, Nanjing

210029

Teva Investigational Site 013, Nanjing

215000

Teva Investigational Site 020, Suzhou

230022

Teva Investigational Site 025, Hefei

300041

Teva Investigational Site 014, Tianjin

310003

Teva Investigational Site 011, Hangzhou

450000

Teva Investigational Site 017, Zhengzhou

510000

Teva Investigational Site 008, Guangzhou

510060

Teva Investigational Site 007, Guangzhou

610041

Teva Investigational Site 010, Chengdu

620102

Teva Investigational Site 024, Lanzhou

710032

Teva Investigational Site 018, Xi'an

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY